Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts
'These cases reflect the power of the jury system and the importance of holding even the most powerful corporations accountable.' Share
Both cases involved claims against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) over its talc-based Baby Powder, which exposed users to asbestos, a known carcinogen.
The 29th-ranked case on the ALM list was a $260 million verdict in Oregon on behalf of Kyung Lee, a 49-year-old mother of three who was diagnosed with mesothelioma after lifelong use of J&J's Baby Powder. Jurors awarded $60 million in compensatory damages and $200 million in punitive damages after finding that Johnson & Johnson knowingly sold asbestos-contaminated products.
The firm also recorded the 82nd-ranked verdict, a $63 million judgment awarded in South Carolina to Michael Perry, a longtime hospitality professional diagnosed with terminal mesothelioma also linked to Johnson & Johnson's talc powder. The jury awarded $32.6 million in compensatory damages and $30.7 million in punitive damages.
'These cases reflect the power of the jury system and the importance of holding even the most powerful corporations accountable,' said Trey Branham, a partner at Dean Omar Branham Shirley. 'Our clients showed incredible strength in telling their stories, and we're honored to have helped secure justice for them.'
Compiled by Law.com's VerdictSearch analysts, the 2024 Top 100 Verdicts list ranks the year's largest jury awards by gross amount. Touted as the most comprehensive roundup of top jury awards nationwide, the list highlights the year's most significant courtroom wins across the country.
View the full list here.
The cases listed are Kyung H. Lee et al. v. Bi-Mart Corporation et al., No. 23-CV-40369 in the Circuit Court of the State of Oregon for the County of Multnomah and Michael Perry v. American International Industries, et al., case number 2023-CP-40-04072 in South Carolina's 5th Judicial Circuit Court.
About Dean Omar Branham Shirley, LLP
Dean Omar Branham Shirley, LLP, is a nationally recognized trial firm that handles cases across the country for individuals who have suffered catastrophic injuries or have died as a result of the irresponsible conduct of others. For more information, visit http://www.dobslegal.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Securities Fraud Investigation Into Biohaven Ltd. (BHVN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Biohaven Ltd. ('Biohaven' or the 'Company') (NYSE: BHVN) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BIOHAVEN LTD. (BHVN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors. Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]' On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025. Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025. On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025. Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Biohaven should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
an hour ago
- Yahoo
Truist announces redemption of senior notes due July 2026
CHARLOTTE, N.C., July 17, 2025 /PRNewswire/ -- Truist Financial Corporation (NYSE: TFC) today announced it will redeem all $1,500,000,000 principal amount outstanding of its floating rate senior notes due July 28, 2026 (CUSIP 89788MAH5) on the redemption date of July 28, 2025. The redemption price for the senior notes will be equal to 100% of the principal amount plus accrued and unpaid interest to, but excluding, the redemption date. Interest on the senior notes will cease to accrue on and after the redemption date. Payment of the redemption price for the senior notes will be made through the facilities of The Depository Trust Company. About TruistTruist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. As a leading U.S. commercial bank, Truist has leading market share in many of the high-growth markets across the country. Truist offers a wide range of products and services through our wholesale and consumer businesses, including consumer and small business banking, commercial banking, corporate and investment banking, wealth management, payments, and specialized lending businesses. Headquartered in Charlotte, North Carolina, Truist is a top-10 commercial bank with total assets of $536 billion as of March 31, 2025. Truist Bank, Member FDIC. Learn more at View original content: SOURCE Truist Financial Corporation
Yahoo
an hour ago
- Yahoo
Credit Quality Takes the Spotlight in American Express Q2 Preview
American Express (NYSE:AXP) reports before the bell on Friday, July 18. Consensus sits at $3.89 EPS and $17.7 billion in revenue, up 8% YoY, with network volume estimated near $466 billion. The first screen will be credit quality and growth optics. The 30-day delinquency rate has stayed around 1.3%, with net write-offs at about 2.1%. A jump into the mid-2s would outweigh any modest revenue beat. Investors also want to see billed business still clipping along in the low-teens, healthy Gen Z and Millennial acquisition, and management holding its 8 to 10% revenue growth and $15.00 to $15.50 EPS full-year guide. Analysts might try to get any management color on stablecoins. Price reaction hinges on those metrics. A clean beat with EPS at or above $3.90, stable credit, and raised guidance might drive the shares through the recent $330 ceiling to fresh highs. Misses tied to credit slippage or a trimmed outlook could see the stock slide toward its 200-day average near $290. Expect the tape to move on credit headlines first, revenue second, and crypto chatter not at all. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
